DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (Amex:AXK) announced today that the company has begun joint research programs with Washington University in St. Louis (WUSTL) School of Medicine and with the Denver Health and Hospital Authority. The two institutions will conduct pre-clinical studies to identify antibiotic resistance mechanisms using Accelr8’s patented analytical methods. The company intends its BACcel® system, in development, to use these methods to speed the diagnosis of life-threatening infections in critically ill patients, and particularly for healthcare-associated infections (HAI). Organisms targeted by the system include the so-called “superbug” multi-drug resistant bacteria such as MRSA, Pseudomonas, Acinetobacter, Klebsiella, E. coli, and related microbes.
